article thumbnail

STAT+: An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

STAT

When Caforio took over in May 2015, Bristol was known as a big pharmaceutical firm with the high-flying stock of a biotechnology company, largely due to its role as the company that brought cancer immunotherapy to market.

article thumbnail

NICE recommends first CAR-T cell therapy on NHS in England

pharmaphorum

Yescarta is administered to the patient via a single intravenous infusion following the administration of a round of chemotherapy designed to accommodate the new cells and minimise the patient’s immune reaction to them. About 50% will ultimately relapse post-transplant.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Rebranded Servier eyes €3bn in cancer drug sales by 2030

pharmaphorum

The strategy to build in cancer dates back to 2015, and has since gathered momentum with the purchase of the oncology businesses of Shire and Agios Pharma in 2018 and 2020, for $2.4 billion and $1.8 billion respectively, as well as smaller deals such as its takeover of Danish antibody specialist Symphogen.

article thumbnail

Daiichi Sankyo claims first okay for oncolytic virus in Japan

pharmaphorum

It’s not the first therapy in the oncolytic virus class to be approved around the world, as that accolade went to Amgen’s Imlygic (talimogene laherparepvec), which was cleared by the FDA for the skin cancer melanoma in 2015. All told, 92% of patients still alive at that time point after Delytact treatment.

article thumbnail

Cold Sore

RX Note

Patients on chemotherapy, oral corticosteroids or drugs for HIV May be susceptible to more severe infection. Cold sores located in the mouth or close to the eye Outside scope of community pharmacy. Lesions that spread away from the lips and onto the face Impetigo more likely.

article thumbnail

First patient given base-edited CAR T cells

European Pharmaceutical Review

Without the experimental CD7 CAR-T cell therapy, having previously undergone unsuccessful conventional treatments including chemotherapy and a bone marrow transplant, the patient’s only other option was palliative care. Six months later, the patient is doing well and is recovering at home. Advanced therapies for difficult to treat diseases.

article thumbnail

Education as the solution to the rare disease ‘diagnostic odyssey’

pharmaphorum

Treatments used today only address clinical manifestations, and not the underlying drivers of the disease, and include chemotherapy and stem cell transplantation – both of which Don has undergone. “I My skin softened dramatically and my lungs remained stable, maybe improved a little bit.